Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
Affiliation:
1. Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles;2. Immune Tolerance Network, Bethesda;3. Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle;4. Benaroya Research Institute, Seattle;5. Division of Allergy-Immunology, Feinberg School of Medicine, Chicago;6. University of Chicago Medicine and Comer Children’s Hospital, Chicago;7. Section of Allergy, Pulmonary and Critical Care, University of Wisconsin Hospital and Clinics, Madison;8. Department of Medicine, Division of Allergy and Clinical Immunology, National Jewish Health, Denver;9. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill;10. Division of Allergy & Clinical Immunology, Johns Hopkins University, Baltimore;11. ASTHMA Inc, Clinical Research Center, Seattle;12. Vital Prospects Clinical Research Institute, Tulsa;13. Immune Tolerance Network, San Francisco;14. Rho Federal Systems Division, Durham;15. National Institutes of Health, Bethesda;p. Immune Tolerance Network, Seattle;1. Department of Respiratory Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain;2. Institut d’Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain;3. Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias, Madrid, Spain;4. Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, Barcelona, Spain;1. Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel;2. Department of Otolaryngology/Head and Neck Surgery, Hadassah Hebrew University Medical Center and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel;1. Diamantina Institute, The University of Queensland, Brisbane, Australia;2. Department of Respiratory & Sleep Medicine, Princess Alexandra Hospital, Brisbane, Australia;1. Department of Medicine V, University Hospital, LMU Munich, Munich, Germany;2. Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), Munich, Germany;1. NIHR Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, UK;2. Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA;3. University of Pittsburgh Asthma Institute, Pittsburgh, PA, USA;4. Department of Respiratory Medicine, Royal Brompton Hospital, London, UK;5. Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA;6. Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK;7. Global Development, Amgen, Thousand Oaks, CA, USA;8. Translational Medicine, Amgen, Thousand Oaks, CA, USA;9. Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA;1. Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany;2. Department of Respiratory and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Beijing, PR China;3. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany
